title: The differences between providing oral health care to HIV-infected children and HIV-infected adults: a general dentist's guide.
abstract: People with HIV and AIDS are living much longer today, thanks to a better understanding of the disease process and the development of effective antiviral drugs and multidrug therapies. Consequently, HIV is now considered a chronic disease, one that affects nearly 40 million people worldwide. Highly active anti-retroviral therapy (HAART), first instituted in 1996, has led to a dramatic reduction in the number of perinatally infected children; however, in 2004, there were still 640,000 children under the age of 15 living with HIV worldwide.1 This population of patients faces more mature health issues compared to most children their age. For example, rampant dental decay is common among children with HIV and requires advanced treatment planning that needs to be closely coordinated with members of the medical team. Maintaining good oral health in combination with medication compliance leads to sustained overall health in HIV-infected children; however, many of the medications these children take have severe adverse effects on their oral health. Furthermore, these medications may interfere with other medications that are prescribed or administered in connection with oral health care. Lastly, the systemic and oral manifestations of HIV and AIDS are different for children than they are for adults; as a result, the prognosis and treatment options for these manifestations vary, depending on the patient's age. This article will address factors that affect the oral health of HIV-infected children and adults, as well as common oral manifestations of HIV and AIDS. Key differences in treatment planning for HIV-infected children and HIV-infected adults will be outlined.
authors.affiliation: Department of Dental Diagnostic Science, University of Texas Health Science Center at San Antonio, USA.
authors.forename: Cara B
authors.initials: CB
authors.lastname: Gonzales
authors.forename: Stacey
authors.initials: S
authors.lastname: Smith
authors.forename: Alicia
authors.initials: A
authors.lastname: Galvan
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Mabry
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000503:physiopathology; D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D002180:Candidiasis, Oral / Q000175:diagnosis; D002648:Child; D002675:Child, Preschool; D019140:Dental Care for Children; D017742:Dental Care for Chronically Ill; D003731:Dental Caries / Q000628:therapy; D003733:Dental Caries Susceptibility; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007223:Infant; D009059:Mouth Diseases / Q000139:chemically induced / Q000175:diagnosis; D010347:Patient Care Planning; D010348:Patient Care Team; D010510:Periodontal Diseases / Q000209:etiology / Q000628:therapy; D053210:Pharmaceutical Preparations, Dental / Q000009:adverse effects; D019562:Viral Load
chemical_list: D053210:Pharmaceutical Preparations, Dental